. Author manuscript; available in PMC: 2011 May 11.

Published in final edited form as: Clin Pharmacol Ther. 2008 Jan 9;84(1):111–118. doi: 10.1038/sj.clpt.6100476

Table 3.

Liver function tests, ERMBT, and docetaxel clearance.

	Liver Function Group
Parameter	Group 1 n = 55	Group 2 n = 10	Group 3A n = 7	Group 3B n = 5
Liver function tests^a
AST (x ULN)	0.9 (0.3 – 3.2)	2.3 (0.6 – 4.7)	5.6 (1.7 – 11)	13 (0.8 – 27)
ALT (x ULN)	0.6 (0.1 – 2.2)	2.1 (0.4 – 6.6)	2.0 (0.6 – 3.1)	3.3 (0.9 – 4.5)
AP ( × ULN)	0.9 (0.4 – 5.0)	2.7 (1.1 – 8.7)	6.2 (2.5 – 15)	5.2 (0.9 – 8.5)
Total bilirubin (x ULN)	0.5 (0.2 – 1.1)	0.4 (0.2 – 0.7)	0.7 (0.4 – 1.0)	2.5 (1.5 – 5.2)
ERMBT^a
C_20min (% dose/min)	0.050 (0.013 – 0.12)	0.061 (0.041 – 0.11)	0.031 (0.0060 – 0.050)	0.019 (0.0055 – 0.062)
Docetaxel unbound clearance (L/h)^b,^c	524 (444) [198 – 1321]	450 (437) [213 – 752]	264 (261) [153 – 378]	139 (96) [64 – 327]

Data are mean (range).

Data are mean (median) [range].

Individual clearance values are from the empirical Bayesian estimates

Abbreviations: n, number of patients; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; ERMBT, erythromycin breath test; C_20min, flux of ¹⁴CO₂ at 20 min after administration of the erythromycin breath test; and ULN, upper limit of institutional normal.